Karyotype complexity and prognosis in acute myeloid leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00064075" target="_blank" >RIV/65269705:_____/16:00064075 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00089323

Výsledek na webu

<a href="http://dx.doi.org/10.1038/bcj.2015.114" target="_blank" >http://dx.doi.org/10.1038/bcj.2015.114</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/bcj.2015.114" target="_blank" >10.1038/bcj.2015.114</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Karyotype complexity and prognosis in acute myeloid leukemia

Popis výsledku v původním jazyce

A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9; 11)(p21 similar to 22; q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with }= 4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9; 11) (p21 similar to 22; q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.

Název v anglickém jazyce

Karyotype complexity and prognosis in acute myeloid leukemia

Popis výsledku anglicky

A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9; 11)(p21 similar to 22; q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with }= 4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9; 11) (p21 similar to 22; q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood cancer journal

ISSN

2044-5385

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

JAN

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

"e386"

Kód UT WoS článku

000369302100010

EID výsledku v databázi Scopus

—